

BEST OF SABCS CROATIA, Zagreb 14. - 15. February 2025.

PROGRAMME

FRIDAY, 14.2.2025.

15:00 Welcome and Introductions

15:10 – 16:30 Section 1.

Moderator: Marijana Jazvić

M. MILKOVIĆ PERIŠA

A Brief History of IHC in Breast Cancer and ASCO CAP Guidelines

A. BUDISAVLJEVIĆ Treatment of Small HER2-positive Tumors in Early-Stage Setting

Ž. VOJNOVIĆ Three-year event-free survival (EFS) of the multicentric phase II TRAIN-3 study evaluating image-guided optimisation of neoadjuvant chemotherapy duration in stage II and III HER-2 positive breast cancer (BOOG 2018 - 01).

J. JOVIĆ ZLATOVIĆ Palbociclib plus letrozole versus weekly paclitaxel , both in combination w/ trastuzumab and pertuzumab , as neoadjuvant treatment for patients w/HR+/HER2+ early breast cancer: primary results from the randomised trial phase II TOUCH trial (IBSCG55-17)

M. BAN HER2+Early Breast Cancer: Post-Neoadjuvant Management for non-pCR

S.PLEŠTINA

AFT-38 PATINA: Randomized, Open Label, Phase III Trial to evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2 positive Metastatic Breast cancer

The satellite symposium section is not a part of the official program
of the Best of SABCS.

16:30 - 17:00 **Satellite Symposium: Eli Lilly**

17:00 – 17:20 Coffee break

The satellite symposium section is not a part of the official program
of the Best of SABCS.

17:20 – 17:50 **Satellite Symposium: Novartis**

17:50 – 18:50 **Section 2.**

Moderator: **Davor Mijatović**

K. ANTUNAC Let's Talk About PBI

N. ŠARIĆ Exclusive endocrine therapy or radiation therapy in women aged 70+ with luminal-like early breast cancer (EUROPA): preplanned interim analysis of a randomized phase 3 trial.

I. MILAS No axillary surgery versus axillary sentinel lymph node biopsy in patients with early invasive breast cancer and breast-conserving surgery: Final primary results of the Intergroup-Sentinel-Mamma (INSEMA) trial.

A. DUJMOVIĆ Surgical prevention and management of Lymphedema

19:00 End of program

SATURDAY, 15.2.2024.

9:00 – 10:00 Section 3.

Moderator: Martina Bašić Koretić

M. JAZVIĆ Ovarian suppression: : Who, When, Why, and for How Long

J. FLAM Primary results of the randomised Phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-/HR+ metastatic breast cancer and indication for chemotherapy - PADMA study

S. BORŠTNAR Imlunestrant, an Oral Selective Estrogen Receptor Degradar (SERD), as Monotherapy and Combined with Abemaciclib, for Patients w/ ER+, HER2- Advanced Breast Cancer (ABC), Pretreated w/ Endocrine Therapy (ET): Results of the Phase 3 EMBER-3 trial. advanced in Triple negative Breast Cancer

N. DEDIĆ PLAVETIĆ Impact of Anthracyclines in High Genomic Risk Node Negative HR+/HER2- Breast Cancer

The satellite symposium section is not a part of the official program
of the Best of SABCS.

10:00 – 10:45 **Satellite Symposium: Astra Zeneca**

10:45 – 11:05 **Coffee break**

11:05 – 12:00 **Section 4.**

Moderator: Ingrid Belac Lovasić

M. PRUTKI Novel Imaging Modalities

Z. MARUŠIĆ Revolutionizing Diagnosis and Discovery with Artificial
Intelligence: Pathology

B. BRKLJAČIĆ AI and Breast Imaginig

The satellite symposium section is not a part of the official program
of the Best of SABCS.

12:00 – 12:30 **Satellite Symposium Novartis**

The satellite symposium section is not a part of the official program
of the Best of SABCS.

12:30 - 13:00 **Satellite Symposium Eli Lilly**

13:00 – 14:00 Lunch/Break

**The satellite symposium section is not a part of the official program
of the Best of SABCS.**

14:00 – 14:20 Satellite Symposium Pfizer

14:20 – 15:30 Section 5.

Moderator : Branka Petrić Miše

- S. TOMIĆ** How to Define Triple Negative Breast Cancer
- T. SILOVSKI** Exploratory Biomarker Analysis of the Phase 3 KEYNOTE 522 study of or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage TNBC.
- A. STRIKIĆ** OlympiA-Phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/gremlin BRCA1/BRCA2 pathogenic variants & HER2-negative primary breast cancer; longer term follow-up
- T. MLINARIĆ KOPRIVANAC** Mind the Gap- Breast Cancer in the Young – Survivorship
- N. ŠARIĆ** Exclusive endocrine therapy or radiation therapy in women aged 70+ with luminal-like early breast cancer (EUROPA): preplanned interim analysis of a randomized phase 3 trial.

15:30 - 16:30 CLINICAL CONTROVERSIES:

**Omission of Axillary Staging in ER Positive Breast Cancer:
Implications on Adjuvant Therapies**

- R. ŽIC** Omission of Axillary Staging in ER+ Disease What is The Data?
- M. SOČE** Omission of Axillary Staging in ER+ Disease: Implications for Radiotherapy
- B. PETRIĆ MIŠE** Omission of Axillary Staging in ER+ Disease: Implications for Adjuvant Systemic Therapy

16:30 – 16:50 Coffee break

16:50 - 17:40 Section 6. YEAR IN THE REVIEW

Moderator: Eduard Vrdoljak

- M. BAŠIĆ KORETIĆ:** Early breast cancer
- E. VRDOLJAK:** Advanced breast cancer

17:40 - 17:55 WHAT WILL WE DO ON MONDAY MORNING?

17:55 Summary and Closing Remarks

18:00 End of the Symposium